Article

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

2021-05-05

Abstract excerpt

Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19 + ), we foun...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 223a07e9-b70b-5832-ac7c-9fdd50d5b169
DOI: 10.1101/2021.04.26.21250357

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosisDOI 10.1101/2021.04.26.21250357Read

CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancerSemantic proximity Read

Incidence and Immunomic Features of Apyretic COVID-19 in Patients Affected by Solid Tumors: a Prospective Cohort Study.Semantic proximity Read

Characteristics and outcome of SARS-CoV-2 infection in cancer patients.Semantic proximity Read

Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer PatientsSemantic proximity Read

Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patientsSemantic proximity Read

MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2Semantic proximity Read

SARS-CoV-2 infection as a potential risk factor for the development of cancerSemantic proximity Read

Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron EraSemantic proximity Read

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity Read

Durable tracking anti-SARS-CoV-2 antibodies of cancer patients recovered from COVID-19Semantic proximity Read

SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147Semantic proximity Read

Scottish COVID CAncer iMmunity Prevalence (SCCAMP) - a longitudinal study of patients with cancer receiving active anti-cancer treatment during the COVID-19 pandemicSemantic proximity Read